Perceptive Advisors: Neurocrine Biosciences NBIX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Venta |
-65,050
| Cerradas | -USD 8.57 M | – | 116 |
|
|
2026
Q1 | USD 8.57 M | Venta |
65,050
-266,000
| -80% | -USD 35.3 M | 0.17% | 68 |
|
|
2025
Q4 | USD 47 M | Venta |
331,050
-119,000
| -26% | -USD 17.2 M | 0.84% | 37 |
|
|
2025
Q3 | USD 63.2 M | Compra |
450,050
+195,000
| +76% | +USD 26.4 M | 1.82% | 18 |
|
|
2025
Q2 | USD 32.1 M | Compra |
255,050
+155,000
| +155% | +USD 17.8 M | 1.19% | 23 |
|
|
2025
Q1 | USD 11.1 M | Sin cambios |
100,050
| – | – | 0.39% | 48 |
|
|
2024
Q4 | USD 13.7 M | Venta |
100,050
-112,178
| -53% | -USD 13.9 M | 0.38% | 51 |
|
|
2024
Q3 | USD 24.5 M | Venta |
212,228
-437,681
| -67% | -USD 60 M | 0.52% | 50 |
|
|
2024
Q2 | USD 89.5 M | Venta |
649,909
-154,500
| -19% | -USD 21.2 M | 2.16% | 11 |
|
|
2024
Q1 | USD 111 M | Compra |
804,409
+533,615
| +197% | +USD 72.9 M | 1.94% | 15 |
|
|
2023
Q4 | USD 35.7 M | Compra |
270,794
+111,552
| +70% | +USD 12.8 M | 0.8% | 39 |
|
|
2023
Q3 | USD 17.9 M | Compra |
159,242
+59,192
| +59% | +USD 6.23 M | 0.6% | 46 |
|
|
2023
Q2 | USD 9.43 M | Sin cambios |
100,050
| – | – | 0.27% | 66 |
|
|
2023
Q1 | USD 10.1 M | Sin cambios |
100,050
| – | – | 0.3% | 66 |
|
|
2022
Q4 | USD 11.9 M | Sin cambios |
100,050
| – | – | 0.34% | 58 |
|
|
2022
Q3 | USD 10.6 M | Venta |
100,050
-297,838
| -75% | -USD 30.2 M | 0.31% | 64 |
|
|
2022
Q2 | USD 38.8 M | Compra |
397,888
+2,249
| +0.6% | +USD 208 k | 1.21% | 22 |
|
|
2022
Q1 | USD 37.1 M | Venta |
395,639
-87,368
| -18% | -USD 7.4 M | 0.77% | 35 |
|
|
2021
Q4 | USD 41.1 M | Sin cambios |
483,007
| – | – | 0.63% | 41 |
|
|
2021
Q3 | USD 46.3 M | Venta |
483,007
-328,825
| -41% | -USD 31.1 M | 0.67% | 37 |
|
|
2021
Q2 | USD 79 M | Venta |
811,832
-130,000
| -14% | -USD 12.5 M | 1.03% | 27 |
|
|
2021
Q1 | USD 91.6 M | Venta |
941,832
-957,383
| -50% | -USD 100 M | 1.16% | 24 |
|
|
2020
Q4 | USD 182 M | Compra |
1,899,215
+350,500
| +23% | +USD 33.9 M | 1.95% | 12 |
|
|
2020
Q3 | USD 149 M | Venta |
1,548,715
-592,695
| -28% | -USD 68.6 M | 2.17% | 14 |
|
|
2020
Q2 | USD 261 M | Venta |
2,141,410
-921,853
| -30% | -USD 102 M | 4.23% | 6 |
|
|
2020
Q1 | USD 265 M | Venta |
3,063,263
-549,291
| -15% | -USD 53.8 M | 6.91% | 3 |
|
|
2019
Q4 | USD 388 M | Venta |
3,612,554
-447,346
| -11% | -USD 46.8 M | 7.71% | 3 |
|
|
2019
Q3 | USD 366 M | Compra |
4,059,900
+36,038
| +0.9% | +USD 3.37 M | 9.86% | 1 |
|
|
2019
Q2 | USD 340 M | Compra |
4,023,862
+265,200
| +7% | +USD 21.8 M | 7.8% | 1 |
|
|
2019
Q1 | USD 331 M | Venta |
3,758,662
-849,892
| -18% | -USD 71 M | 9.34% | 1 |
|
|
2018
Q4 | USD 315 M | Venta |
4,608,554
-168,700
| -4% | -USD 16.2 M | 12% | 1 |
|
|
2018
Q3 | USD 587 M | Compra |
4,777,254
+62,004
| +1% | +USD 7.03 M | 15.71% | 1 |
|
|
2018
Q2 | USD 463 M | Venta |
4,715,250
-46,739
| -1% | -USD 4.18 M | 12.14% | 1 |
|
|
2018
Q1 | USD 395 M | Venta |
4,761,989
-389,600
| -8% | -USD 32.9 M | 11.06% | 1 |
|
|
2017
Q4 | USD 400 M | Compra |
5,151,589
+360,000
| +8% | +USD 24.6 M | 13.25% | 1 |
|
|
2017
Q3 | USD 294 M | Compra |
4,791,589
+1,214,000
| +34% | +USD 64.1 M | 11.28% | 1 |
|
|
2017
Q2 | USD 165 M | Compra |
3,577,589
+211,059
| +6% | +USD 10.2 M | 8.28% | 2 |
|
|
2017
Q1 | USD 146 M | Compra |
3,366,530
+50,007
| +2% | +USD 2.14 M | 8.3% | 1 |
|
|
2016
Q4 | USD 128 M | Compra |
3,316,523
+840,251
| +34% | +USD 38 M | 9.13% | 1 |
|
|
2016
Q3 | USD 125 M | Venta |
2,476,272
-321,695
| -11% | -USD 16 M | 8.09% | 2 |
|
|
2016
Q2 | USD 127 M | Compra |
2,797,967
+77,000
| +3% | +USD 3.55 M | 8.82% | 2 |
|
|
2016
Q1 | USD 108 M | Compra |
2,720,967
+224,800
| +9% | +USD 8.92 M | 9.44% | 2 |
|
|
2015
Q4 | USD 141 M | Venta |
2,496,167
-446,800
| -15% | -USD 22.7 M | 10.45% | 2 |
|
|
2015
Q3 | USD 117 M | Venta |
2,942,967
-341,500
| -10% | -USD 16.5 M | 9.35% | 2 |
|
|
2015
Q2 | USD 157 M | Venta |
3,284,467
-456,800
| -12% | -USD 19.4 M | 9.45% | 2 |
|
|
2015
Q1 | USD 149 M | Compra |
3,741,267
+176,000
| +5% | +USD 6.3 M | 11.55% | 2 |
|
|
2014
Q4 | USD 79.6 M | Venta |
3,565,267
-1,000,000
| -22% | -USD 18.9 M | 6.68% | 2 |
|
|
2014
Q3 | USD 71.5 M | Venta |
4,565,267
-34,600
| -0.8% | -USD 517 k | 7.24% | 2 |
|
|
2014
Q2 | USD 68.3 M | Venta |
4,599,867
-19,500
| -0.4% | -USD 275 k | 6.7% | 2 |
|
|
2014
Q1 | USD 74.4 M | Compra |
4,619,367
+435,630
| +10% | +USD 7.45 M | 7.81% | 2 |
|
|
2013
Q4 | USD 39.1 M | Venta |
4,183,737
-86,967
| -2% | -USD 849 k | 4.69% | 6 |
|
|
2013
Q3 | USD 48.3 M | Venta |
4,270,704
-811,013
| -16% | -USD 11.1 M | 3.92% | 8 |
|
|
2013
Q2 | USD 68 M | Sin cambios |
5,081,717
| – | – | 6.86% | 3 |
|
Otros fondos que tienen NBIX en su portafolio
Posición de Perceptive Advisors en NBIX: resumen de T2 2026
Perceptive Advisors liquidó su posición en Neurocrine Biosciences (NBIX) en T2 2026: cerró una participación de 65,050 acciones, con ventas por un valor estimado de USD 8.57 M.
Perceptive Advisors reportó por primera vez una posición en NBIX en T2 2013 y la mantuvo en 52 trimestres. La posición alcanzó su máximo de USD 587 M en T3 2018. Al cierre de T2 2026, 785 fondos que sigue Wall St. Rank mantienen una posición en NBIX.
- Perceptive Advisors reportó que ya no tenía una posición en Neurocrine Biosciences al cierre de T2 2026, después de venderla por completo durante el trimestre.
- Perceptive Advisors vendió 65,050 acciones de Neurocrine Biosciences en T2 2026, por un valor estimado de USD 8.57 M.
- Perceptive Advisors reportó por primera vez una posición en Neurocrine Biosciences en T2 2013 y la mantuvo en 52 trimestres.
- La posición de Perceptive Advisors en Neurocrine Biosciences alcanzó su máximo de USD 587 M en T3 2018.
- Al cierre de T2 2026, 785 fondos que sigue Wall St. Rank tenían Neurocrine Biosciences en su portafolio.
Según el informe 13F de Perceptive Advisors correspondiente a T2 2026, presentado el 14 ago 2026.